TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pregabalin in Treating Women With Hot Flashes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Meeting 1 of the following criteria:~  * History of breast cancer (currently without malignant disease)~ * No history of breast cancer, but patient wishes to avoid estrogen due to a perceived increased risk of breast cancer~* Bothersome hot flashes (defined by their occurrence ≥ 28 times per week and of sufficient severity to make the patient desire therapeutic intervention)~* Presence of hot flashes for ≥ 1 month prior to study entry~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Life expectancy ≥ 6 months~* Able to complete questionnaire(s) by themselves or with assistance~* Women of childbearing potential not eligible (per the judgment of the attending clinician)~* Serum creatinine ≤ 1.5 times upper limit of normal~PRIOR CONCURRENT THERAPY:~* No prior gabapentin or pregabalin~* More than 4 weeks since prior and no concurrent antineoplastic chemotherapy, androgens, estrogens, or progestational agents~  * Vaginal estrogen is allowed if used for the past month and not planned to be discontinued~* Concurrent adjuvant targeted therapy (i.e., lapatinib, trastuzumab \[Herceptin®\]) allowed in patients with no evidence of disease~* Concurrent tamoxifen, raloxifene, or aromatase inhibitors on a constant dose for at least 4 weeks allowed provided the medication will not be stopped during the study period~* No concurrent or planned use of other agents for hot flashes except for any of the following:~  * Stable dose of vitamin E is allowed as long as agent was started \> 30 days prior to study initiation and is to be continued throughout the study period~ * Soy is allowed, if it is planned to be continued at the same dose during the study period~ * Stable dose of antidepressants is allowed as long as it was started \> 30 days prior to study initiation and is to be continued at a stable dose throughout the study period

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Pregabalin75 (Type: EXPERIMENTAL): Patients receive 75 mg of oral pregabalin twice daily for 6 weeks.
- Pregabalin150 (Type: EXPERIMENTAL): Patients receive 150 mg of oral pregabalin twice daily for 6 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients receive oral placebo twice daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cluster of differentiation 20 (CD20)-positive, follicular Non-Hodgkin's lymphoma grade 1, 2, 3a. A tumor biopsy must have been performed within 6 months before study entry with material available for central review~* No prior treatment~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~Exclusion Criteria:~* Grade 3b follicular lymphoma~* Transformation to high-grade lymphoma secondary to follicular lymphoma~* Types of Non-Hodgkin's lymphoma other than follicular lymphoma~* Presence or history of central nervous system (CNS) disease~* Corticoid therapy during the last 4 weeks, except prednisone treatment less than (\<) 20 milligrams per day (mg per day)~* Known active bacterial, viral, fungal, or mycobacterial, or any major episode of infections requiring hospitalization or treatment with IV antibiotics within 4 weeks of start of study medication, or oral antibiotics within 2 weeks prior to start of study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stage I and II: Rituximab IV + Chemotherapy (CHOP/CVP) (Type: ACTIVE_COMPARATOR): Eight cycles of rituximab IV infusion (375 mg/m\^2; rituximab induction) in combination with up to 8 cycles of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) or cyclophosphamide, vincristine, prednisolone (CVP) chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m\^2) once every 8 weeks for 24 months.
- Stage I and II: Rituximab SC + Chemotherapy (CHOP/CVP) (Type: EXPERIMENTAL): First cycle of rituximab IV infusion (375 mg/m\^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in combination with up to 8 cycles of CHOP or CVP chemotherapy (as per institutional practice) administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VERifynow in DIabetes Non-responsiveness: a Study on Switching From Clopidogrel to Prasugrel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Type 2 diabetic patients with acute coronary syndrome with non-ST segment elevation who are undergoing a percutaneous coronary intervention (PCI) with a coronary stent.~2. Patients who are non-responsive on the platelet anti-aggregation test with standard doses of clopidogrel will be randomized.~3. Participants must sign an informed consent document.~Exclusion Criteria:~1. Age \<18 years or \>80 years.~2. Patients with acute coronary syndrome with ST segment elevation.~3. Pregnancy previous to or during the study.~4. The use of oral anticoagulants in the last 10 days with an INR \>1.5 or who plan to use them during the follow-up period (1 year).~5. Antithrombotic treatment with GP IIb/IIIa inhibitors.~6. Contraindication for the use of prasugrel and/or clopidogrel and/or aspirin:~   * Antecedents of pharmacologic allergy to thienopyridine derivatives or aspirin.~  * Antecedents of clinically significant or persistent thrombocytopenia or neutropenia.~7. Active bleeding or significant increase of risk of hemorrhage such as severe hepatic insufficiency, peptic ulcer present, proliferative diabetic retinopathy, antecedents of severe systemic bleeding, gastrointestinal bleeding, macrohematuria, intraocular hemorrhage, hemorrhagic stroke, or intracranial bleeding), or other antecedents of bleeding diathesis or coagulopathy.~8. Patients with previous TIA or CVA.~9. Patients weighing \<60 Kg.~10. Hemoglobin \<10.5 g/dl, or Hematocrit \<30%.~11. Severe left ventricular systolic dysfunction, EF \<35%.~12. Renal insufficiency with creatinine levels \>2 mg/dl.~13. Previous inclusion of the patient in another study.~14. Treatment in research (medication or device) in the last 30 days prior.~15. Medical, geographical, or social factors that would make participation in the study impractical, such as the incapacity to provide written informed consent and to understand the complete meaning of informed consent, or the refusal of the patient to participate in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Clopidogrel (Type: ACTIVE_COMPARATOR): This group will receive after PCI the standard dose of clopidogrel, a daily dose of 75 mg.
- Prasugrel (Type: EXPERIMENTAL): This group will receive after PCI a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by a daily dose of prasugrel (10 mg tablet).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 3 months old living in the aera for the next 2 years, exlusive use of the study health facilities~Exclusion Criteria:~* Known chronic illness, e.g. TB, diabetes, renal failure severe malnutrition (weight-for-age (WAZ) \< 60% percentile) severe anaemia (Hb \< 5 g/dl), or permanent disability, that prevents or impedes study participation

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 4 Months
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 1 day Sulfadoxine/Pyrimethamine + 3 days Amodiaquine
- 2 (Type: ACTIVE_COMPARATOR): 1 day of Sulfadoxine/Pyrimthamine and 3 days of Artesunate
- 3 (Type: PLACEBO_COMPARATOR): children of this gorup will receive only placebo dugs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of a Pandemic Influenza Vaccine in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Healthy children aged greater or equal to 6 months to less than 9 years~* Normal gestation period~Exclusion Criteria:~* History of clinically significant medical conditions~* History of Guillain Barre syndrome or active neurological disease

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 8 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of GS-5806 in Healthy Volunteers Infected With Respiratory Syncytial Virus (RSV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male or female~* Between 18 to 45 years old~* Body Mass Index of 18 to 33 kg/m2~Exclusion Criteria:~* Acute or chronic medical illness~* Positive for Human Immunodeficiency Virus, Hepatitis B or C~* Nose or nasopharynx abnormalities~* Abnormal lung function

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- GS-5806 (Type: EXPERIMENTAL): GS-5806, powder for oral solution
- Sugar powder for oral solution in juice (Type: PLACEBO_COMPARATOR): Sugar powder for oral solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy of Experimental Gel to Foam Dentifrices in Dental Erosion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* General and Oral Health: Good general health with (in the opinion of the investigator) no clinically OST and OHT examinations.~* Oral Requirements:~  * An intact maxillary dental arch suitable for the retention of the palatal appliance and an intact mandibular dental arch. Subjects may have fixed bridges replacing missing teeth.~ * A gum base stimulated whole saliva flow rate ≥ 0.8 g/min and an unstimulated whole saliva flow rate ≥ 0.2 g/min.~* Contraception: Women of childbearing potential who are, in the opinion of the investigator, practicing a reliable method of contraception.~Exclusion Criteria:~* Oral Health:~  * Current active caries or periodontal disease that may compromise the study or the health of the subjects.~ * Lesions of the oral cavity that could interfere with the study evaluations, including severe gingivitis, grossly carious lesions, periodontitis and other severe periodontal disease.~* Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.~* Clinical Study/Experimental Medication:~  * Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit~ * Previous participation in this study~* Substance abuse: Recent history (within the last year) of alcohol or other substance abuse.~* Pregnancy: Women who are pregnant or who are intending to become pregnant over the duration of the study~* Breast-feeding: Women who are breast-feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- NaF/KNO3 toothpaste, Low RDA (Type: EXPERIMENTAL): Participants to brush with 1.5 g of low RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% weight by weight (w/w) KNO3.
- NaF/KNO3 toothpaste, Medium RDA (Type: EXPERIMENTAL): Participants to brush with 1.5 g of medium RDA gel to foam toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
- NaF/KNO3 toothpaste (Type: ACTIVE_COMPARATOR): Participants to brush with 1.5 g of NaF/KNO3 toothpaste containing 1450 ppm F - EU level as NaF. All study treatments contain 5% w/w KNO3.
- No fluoride/KNO3 toothpaste (Type: PLACEBO_COMPARATOR): Participants to brush with a fluoride free toothpaste (0 ppmF). All study treatments contain 5% w/w KNO3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 2 Doses of an Approved Drug Being Studied for a New Indication for the Prevention of Postoperative Nausea and Vomiting (0869-091)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is at least 18 years of age.~* Patient is scheduled to undergo open abdominal surgery requiring overnight hospital stay (24-hour hospital stay after end of surgery).~* Patient is scheduled to receive general anesthesia.~* Patient is scheduled to receive postoperative opioids.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of CPT-11, Raltegravir and Midazolam With Characterisation of UGT1A1 Genotype

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically proven solid tumour for which CPT-11 given by the Folfiri regimen is indicated and prescribed by the attending physician.~* Age above 21 years.~* Measurable or evaluable disease~* Karnofsky performance status \> 70%~* Life expectancy \> 3 months~* WBC \> 3.0 x 103/?l; ANC \> 1500/?l~* Hemoglobin \> 9.0 g/dl~* Platelets \> 100000/?l~* Creatinine \< 1.5 x ULN or calculated creatinine clearance \> 40 ml/min~* Total bilirubin \< 1.5 x ULN~* SGOT, SGPT \< 5 x ULN unless due to disease~Exclusion Criteria:~* Biologic therapy or chemotherapy within 4 weeks. (Six weeks for prior nitrosoureas or mitomycin C).~* Radiation therapy within 4 weeks if \> 25% of bone marrow was irradiated.~* Have not received any medications that are known to be metabolised by UGT1A1 within 30 days of the first dose of CPT-11.~* Short gut syndrome or other causes of malabsorption.~* Colony stimulating factors within 2 weeks.~* Women of childbearing potential not practicing birth control. (Note: by means other than oral contraception)~* Pregnant women~* Severe peripheral neuropathy grade 2 or higher.~* Medical or psychiatric conditions which may impair the patient's ability to provide informed consent.~* Hypersensitivity to CPT-11, raltegravir or midazolam/other benzodiazepines.~* Rapidly progressive intracranial or spinal metastatic disease.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CPT-11 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* 18 to 82 years of age, inclusive~* Chronic Kidney Disease with a GFR category of G3a-G5 and not yet on dialysis~* eGFR ≥ 10 and ≤ 65 mL/minute/1.73 m2~* Anemia secondary to CKD with an ESA status and a Screening HGB as per protocol~* Iron replete with ferritin and TSAT levels as defined per protocol~Key Exclusion Criteria:~* BMI \> 44.0 kg/m2~* Red blood cell transfusion within 11 weeks prior to the Screening visit~* Androgen therapy within the previous 21 days prior to the Screening visit~* Intravenous iron within the past 4 weeks prior to the Screening visit~* AST or ALT \>1.8x ULN, alkaline phosphatase \>2x ULN, or total bilirubin \>1.5x ULN~* Screening ECG with QTc \> 500 msec~* Uncontrolled hypertension~* Class III or IV congestive heart failure~* Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to the Screening visit

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 82 Years
- Healthy Volunteers: f

Study Arms:
- AKB-6548 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bioequivalence Study of Telmisartan Between Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg (T80/A5/H12.5 mg) Fixed-dose Combination (FDC) Tablet and T80/H12.5 mg Tab and A5 mg (Encap A2.5 mg Tab x2) Concomitant Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Healthy male subjects age \>=20 and \<=35 years; body weight: \>=50 kg and \<=80 kg; body mass index: \>=18.0 and \<=25.0 kg/m2~* Without any clinically significant findings and complications on the basis of a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR), body temperature)~* Signed and dated written informed consent prior to admission to the trial in accordance with the Good Clinical Practice (GCP) and the local legislation~Exclusion criteria:~- Any finding of the medical examination (including BP, PR and ECGs) deviating from normal and of clinical relevance

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- T80/A5/H12.5 mg FDC (Type: EXPERIMENTAL): Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet
- T80/H12.5 FDC + A5 mono (Type: ACTIVE_COMPARATOR): Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg fixed dose combination tablet and Amlodipine 5 mg capsule

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Tolerability, and Safety Study of DFN-15

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A history of episodic migraine, who experience 2 to 8 migraine attacks per month for at least the past 12 months, with no more than 14 headache days per month, and with 48 hours of headache-free time between migraine attacks.~2. Patients who have migraine with or without aura with onset before age 50 years~3. Report usual migraine pain of 2 (moderate) or 3 (severe) on headache pain severity scale without treatment.~4. Subjects who are willing and able to:~   1. Evaluate and record pain, migraine symptoms, and study drug effectiveness information in real-time using a subject eDiary for the duration of the study;~  2. Record each instance of the use of study drug and rescue medication in real-time using a subject eDiary for the duration of the study;~  3. Comply with all other study procedures and scheduling requirements.~Exclusion Criteria:~1. Minors, even if they are in the specified study age range~2. Medication overuse:~   1. Opioids greater than or equal to 10 days during the 90 days prior to screening~  2. Combination medications (e.g., Fiorinal®) greater than or equal to 10 days during the 90 days prior to screening (applies only if includes opioid and/or barbiturate)~  3. Nonsteroidal Anti-inflammatory Drugs or other simple medications greater than 14 days a month during the 90 days prior to screening~  4. Triptans or ergots greater than or equal to 10 days a month during the 90 days prior to screening~3. Treated with onabotulinumtoxin A (Botox®) for migraine within 4 months prior to screening. (If treated for cosmetic reasons, subjects may be included).~4. Current treatment with antipsychotics or use of antipsychotics within 30 days prior to randomization.~5. Patients who have received treatment with an investigational drug or device within 30 days of randomization, or participated in a central nervous system clinical trial within 2 months prior to randomization~6. Patients with positive screening test for human immunodeficiency virus \[HIV\], positive hepatitis B surface antigen (HBsAg), or positive hepatitis C virus \[HCV\] antibody~7. Subjects who are employees or immediate relatives of the employees of the Sponsor, any of its affiliates or partners, or of the clinical research study site.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DFN-15 Active (Type: EXPERIMENTAL): DFN-15 Active
- DFN-15 Placebo (Type: PLACEBO_COMPARATOR): DFN-15 Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete